Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - fluconazole - solution for infusion - 2mg/1ml

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 10 mg/ml;  ;   - powder for oral suspension - 10 mg/ml - active: fluconazole 10 mg/ml     excipient: citric acid colloidal silicon dioxide orange flavour 57458 ap05514 sodium benzoate sodium citrate dihydrate sucrose titanium dioxide xanthan gum - cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. diflucan can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids.

Nýja-Sjáland - enska - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 40 mg/ml;  ;   - powder for oral suspension - 40 mg/ml - active: fluconazole 40 mg/ml     excipient: annatto citric acid colloidal silicon dioxide sodium benzoate sodium citrate dihydrate sucrose titanium dioxide xanthan gum - cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. diflucan can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids.

Írland - enska - HPRA (Health Products Regulatory Authority)

noridem enterprises limited - fluconazole - solution for infusion - 2 milligram(s)/millilitre - triazole derivatives; fluconazole

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extens

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - fluconazole, quantity: 2 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - indications as at 21 may 2004 : diflucan, given orally, is indicated for: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note : data suggest that the clinical efficacy of diflucan is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with aids. 3. treatment of oropharyngeal and oesophageal candidiasis in aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with hiv infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note : it remains to be shown that diflucan is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice. 6. vaginal candidiasis when topical therapy has failed. 7. treatment of extens

Singapúr - enska - HSA (Health Sciences Authority)

pfizer private limited - fluconazole - injection - 2 mg/ml - fluconazole 2 mg/ml

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fareva amboise - fluconazole - solution for i/v infusion - 2mg/ml

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fareva amboise - fluconazole - solution for i/v infusion - 2mg/ml

Armenía - enska - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

fareva amboise - fluconazole - solution for i/v infusion - 2mg/ml